BPC-157 (Pentadecapeptide)

The Stability Claim, Examined

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

The claim is specifically about resistance to degradation in human gastric juice, an environment that destroys most peptides within minutes. Its proline content gives a plausible structural basis. It does not mean the peptide is indefinitely stable in solution or resistant to all proteases.

Key facts

The claim
Stable in human gastric juice
Structural basis
Four prolines, three consecutive
Why proline helps
Proline-adjacent bonds resist most proteases
Does not mean
Indefinite solution stability
Does not mean
Resistance to every protease
Still applies
Chemical hydrolysis over time

What kind of stability is being claimed

Enzymatic and acidic stability in a specific environment. Gastric juice combines a pH around 1.5 to 3.5 with pepsin, and most peptides do not survive it. The claim is that BPC-157 does, which is a narrow and testable proposition rather than a general assertion of robustness.

Why the structure makes it plausible

Proteases require an extended backbone conformation at their active site, and proline prevents the backbone adopting it nearby. BPC-157 has four prolines including a run of three, which places a substantial fraction of its bonds in protease-resistant contexts. This is the same principle that Semax and Selank exploit with their Pro-Gly-Pro extensions, applied more extensively.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

What the claim does not cover

Chemical hydrolysis, which proceeds without enzymes and is why lyophilised storage matters. Oxidation, though the absence of cysteine and methionine largely removes that route here. And stability in other environments: resistance to pepsin at low pH does not predict resistance to a different protease in a different compartment.

Why it does not follow that oral administration works

This inference is commonly made and it does not hold. Surviving the stomach is one of three barriers to oral bioavailability. The others are enzymatic degradation in the small intestine by trypsin and chymotrypsin, and crossing the intestinal epithelium; a large, polar, charged fifteen-residue peptide is not a promising candidate for passive permeation. Gastric stability addresses the first barrier only.

Whose claim it is

The stability characterisation comes from the Zagreb group, along with most of the compound's literature. As with everything else in this category, that concentration means the finding is less independently established than its frequency of repetition suggests.

Frequently asked questions

Is BPC-157 stable?

The claim is specifically resistance to degradation in gastric juice, supported structurally by its proline content. It is not a claim of indefinite or universal stability.

Does gastric stability mean it works orally?

No. Surviving the stomach is one of three barriers; intestinal proteases and epithelial permeability are the others.

Does it still need cold storage?

Yes. Enzymatic stability says nothing about chemical hydrolysis, which is why lyophilised material is stored cold and dry.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.